Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands
Maria Skaalum Petersen, Marin Strøm, Debes Hammershaimb Christiansen, Jógvan Páll Fjallsbak, Eina H. Eliasen, Malan Johansen, Anna Sofía Veyhe, Marnar Fríðheim Kristiansen, Shahin Gaïni, Lars Møller, Bjarni á Steig, Pál Weihe
Abstract
We conducted a nationwide study of the prevalence of severe acute respiratory syndrome coronavirus 2 infection in the Faroe Islands. Of 1,075 randomly selected participants, 6 (0.6%) tested seropositive for antibodies to the virus. Adjustment for test sensitivity and specificity yielded a 0.7% prevalence. Our findings will help us evaluate our public health response.
Topics & Concepts
SeroprevalenceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)MedicineAntibodyVirology2019-20 coronavirus outbreakCoronavirusPublic healthImmunologySerologyInternal medicineOutbreakPathologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing